Avita Medical (RCEL) Competitors $5.17 -0.10 (-1.90%) Closing price 04:00 PM EasternExtended Trading$5.23 +0.06 (+1.24%) As of 07:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RCEL vs. BVS, BFLY, KIDS, DCTH, AXGN, SMLR, TMCI, NPCE, OM, and CLPTShould you be buying Avita Medical stock or one of its competitors? The main competitors of Avita Medical include Bioventus (BVS), Butterfly Network (BFLY), OrthoPediatrics (KIDS), Delcath Systems (DCTH), AxoGen (AXGN), Semler Scientific (SMLR), Treace Medical Concepts (TMCI), NeuroPace (NPCE), Outset Medical (OM), and ClearPoint Neuro (CLPT). These companies are all part of the "medical equipment" industry. Avita Medical vs. Its Competitors Bioventus Butterfly Network OrthoPediatrics Delcath Systems AxoGen Semler Scientific Treace Medical Concepts NeuroPace Outset Medical ClearPoint Neuro Bioventus (NYSE:BVS) and Avita Medical (NASDAQ:RCEL) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, risk, valuation, earnings, dividends and media sentiment. Do institutionals and insiders have more ownership in BVS or RCEL? 62.9% of Bioventus shares are held by institutional investors. Comparatively, 27.7% of Avita Medical shares are held by institutional investors. 33.0% of Bioventus shares are held by insiders. Comparatively, 2.8% of Avita Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Which has stronger valuation & earnings, BVS or RCEL? Avita Medical has lower revenue, but higher earnings than Bioventus. Bioventus is trading at a lower price-to-earnings ratio than Avita Medical, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioventus$567.70M0.99-$156.23M-$0.48-14.27Avita Medical$64.25M2.13-$61.85M-$2.19-2.36 Do analysts recommend BVS or RCEL? Bioventus presently has a consensus price target of $14.33, suggesting a potential upside of 109.25%. Avita Medical has a consensus price target of $16.50, suggesting a potential upside of 219.15%. Given Avita Medical's stronger consensus rating and higher possible upside, analysts plainly believe Avita Medical is more favorable than Bioventus.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bioventus 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Avita Medical 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 Which has more risk and volatility, BVS or RCEL? Bioventus has a beta of 0.86, suggesting that its share price is 14% less volatile than the S&P 500. Comparatively, Avita Medical has a beta of 1.52, suggesting that its share price is 52% more volatile than the S&P 500. Does the media favor BVS or RCEL? In the previous week, Avita Medical had 1 more articles in the media than Bioventus. MarketBeat recorded 2 mentions for Avita Medical and 1 mentions for Bioventus. Bioventus' average media sentiment score of 1.11 beat Avita Medical's score of 0.62 indicating that Bioventus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Avita Medical 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BVS or RCEL more profitable? Bioventus has a net margin of -7.11% compared to Avita Medical's net margin of -79.61%. Bioventus' return on equity of 15.61% beat Avita Medical's return on equity.Company Net Margins Return on Equity Return on Assets Bioventus-7.11% 15.61% 4.01% Avita Medical -79.61%-632.62%-71.72% SummaryBioventus and Avita Medical tied by winning 8 of the 16 factors compared between the two stocks. Get Avita Medical News Delivered to You Automatically Sign up to receive the latest news and ratings for RCEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RCEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RCEL vs. The Competition Export to ExcelMetricAvita MedicalMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$139.31M$2.42B$5.54B$8.87BDividend YieldN/A1.77%5.39%4.10%P/E Ratio-2.368.7226.1719.90Price / Sales2.13663.86414.67113.66Price / CashN/A151.5836.1356.90Price / Book30.414.548.055.38Net Income-$61.85M$31.16M$3.15B$248.50M7 Day Performance8.39%0.15%1.85%2.97%1 Month Performance-14.40%8.81%4.81%6.02%1 Year Performance-34.39%2.55%34.86%20.39% Avita Medical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RCELAvita Medical1.1277 of 5 stars$5.17-1.9%$16.50+219.1%-31.7%$139.31M$64.25M-2.36130BVSBioventus3.3926 of 5 stars$6.52-0.5%$14.33+119.8%+21.6%$535.58M$567.70M-10.691,200Positive NewsBFLYButterfly Network2.2104 of 5 stars$2.05-1.4%$4.00+95.1%+118.5%$514.36M$82.06M-7.07460News CoverageAnalyst ForecastKIDSOrthoPediatrics4.2374 of 5 stars$20.59+1.5%$35.83+74.0%-22.5%$492.77M$204.73M-11.77200DCTHDelcath Systems3.6145 of 5 stars$13.26-4.3%$24.00+81.0%+54.5%$482.34M$37.21M-26.5260Gap DownAXGNAxoGen2.6976 of 5 stars$9.79+0.6%$22.20+126.8%+42.2%$443.14M$187.34M-65.26450Positive NewsSMLRSemler Scientific2.3008 of 5 stars$41.99+16.2%$71.00+69.1%+5.0%$403.02M$56.29M-16.09120Gap UpHigh Trading VolumeTMCITreace Medical Concepts2.5924 of 5 stars$5.74+4.2%$10.16+77.0%-7.2%$346.52M$209.36M-6.75250NPCENeuroPace3.2631 of 5 stars$10.57+1.5%$15.50+46.6%+43.2%$341.43M$79.91M-12.58170High Trading VolumeOMOutset Medical1.6856 of 5 stars$17.37-8.5%$27.00+55.4%-62.5%$336.37M$113.69M-0.60520News CoverageHigh Trading VolumeCLPTClearPoint Neuro2.2883 of 5 stars$11.36+0.9%$25.00+120.1%+111.3%$315.16M$31.39M-14.95110Positive News Related Companies and Tools Related Companies Bioventus Alternatives Butterfly Network Alternatives OrthoPediatrics Alternatives Delcath Systems Alternatives AxoGen Alternatives Semler Scientific Alternatives Treace Medical Concepts Alternatives NeuroPace Alternatives Outset Medical Alternatives ClearPoint Neuro Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RCEL) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avita Medical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avita Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.